Research Articles

Comparative Design, In Silico Dockingand Predictive ADME/ TOX Properties of Some Novel 2, 4-hydroxy Derivatives of Thiazolidine-2, 4-diones as PPARγ Modulator

Vol. 4 No. 2 (2017) 11-19 Published May 25, 2017

1,456 Views428 Downloads4 Citations

PDF

Abstract

Peroxisome proliferated receptors (PPARs) are important targets for drugs used in the treatment of various metabolic disorders. We have reported 4-hydroxy benzylidene derivatives of thiazolidine-2,4-diones with reversed orientation in the active site of PPARγin our earlier communication. With the reversed conformation of TZD, fitting the established pharmacophore was discussed. The current simulation studies revolves around the 2,4-dihydroxy benzylidene derivatives expecting H-bonding interactions similar to Rosiglitazone’s acidic head. The docking protocol was validated by enrichment studies using decoys and actives from DUD. Designed compounds were showing interactions similar to the actives in the top 10%, 5% and 1%. They also exhibited H-bonding interactions similar to their monohydroxy counterparts without any additional H-bonding interactions due to introduction of additional hydroxy functional groups. Predicted ADMET report reveals that 5 molecules show favourable hERG-I and -II properties and nine compounds show best metabolic stability.

References

  1. Cockram, C., The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Med J 2000, 6 (1), 43-52.
  3. Hunt, K. J.; Schuller, K. L., The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am 2007, 34 (2), 173-199.
  4. https://doi.org/10.1016/j.ogc.2007.03.002 DOI: https://doi.org/10.1016/j.ogc.2007.03.002
  6. Elbrecht, A.; Chen, Y.; Cullinan, C. A.; Hayes, N.; Leibowitz, M. D.; Moller, D. E.; Berger, J., Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors ?1 and ?2. Biochem Biophys Res Comm 1996, 224 (2), 431-437.
  7. https://doi.org/10.1006/bbrc.1996.1044 DOI: https://doi.org/10.1006/bbrc.1996.1044
  9. Mukherjee, R.; Jow, L.; Croston, G. E.; Paterniti, J. R., Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR?2 versus PPAR?1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997, 272 (12), 8071-8076.
  10. https://doi.org/10.1074/jbc.272.12.8071 DOI: https://doi.org/10.1074/jbc.272.12.8071
  12. Kota, B. P.; Huang, T. H.-W.; Roufogalis, B. D., An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51 (2), 85-94.
  13. https://doi.org/10.1016/j.phrs.2004.07.012 DOI: https://doi.org/10.1016/j.phrs.2004.07.012
  15. Lehrke, M.; Lazar, M. A., The many faces of PPAR?. Cell 2005, 123 (6), 993-999.
  16. https://doi.org/10.1016/j.cell.2005.11.026 DOI: https://doi.org/10.1016/j.cell.2005.11.026
  18. Daynes, R. A.; Jones, D. C., Emerging roles of PPARs in inflammation and immunity. Nature Rev Immunol 2002, 2 (10), 748-759.
  19. https://doi.org/10.1038/nri912 DOI: https://doi.org/10.1038/nri912
  21. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. G.; Brown, P. J.; Sternbach, D. D.; Lehmann, J. M.; Wisely, G. B.; Willson, T. M., Molecular recognition of fatty acids by peroxisome proliferator–activated receptors. Mol Cell 1999, 3 (3), 397-403.
  22. https://doi.org/10.1016/S1097-2765(00)80467-0 DOI: https://doi.org/10.1016/S1097-2765(00)80467-0
  24. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M., The structure-activity relationship between peroxisome proliferator-activated receptor ? agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996, 39 (3), 665-668.
  25. https://doi.org/10.1021/jm950395a DOI: https://doi.org/10.1021/jm950395a
  27. Chadha, N.; Bahia, M. S.; Kaur, M.; Silakari, O., Thiazolidine-2, 4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions. Bioorg Med Chem 2015, 23 (13) 2953-2974.
  28. https://doi.org/10.1016/j.bmc.2015.03.071 DOI: https://doi.org/10.1016/j.bmc.2015.03.071
  30. Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamatsu, Y.; Iwatsuka, H.; Suzuoki, Z., Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2, 4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 1983, 32 (9), 804-810. DOI: https://doi.org/10.2337/diabetes.32.9.804
  31. https://doi.org/10.2337/diab.32.9.804 DOI: https://doi.org/10.2337/diab.32.9.804
  33. Parulkar, A. A.; Pendergrass, M. L.; Granda-Ayala, R.; Lee, T. R.; Fonseca, V. A., Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001, 134 (1), 61-71.
  34. https://doi.org/10.7326/0003-4819-134-1-200101020-00014 DOI: https://doi.org/10.7326/0003-4819-134-1-200101020-00014
  36. Azoulay, L.; Yin, H.; Filion, K. B.; Assayag, J.; Majdan, A.; Pollak, M. N.; Suissa, S., The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012, 344, e3645.
  37. https://doi.org/10.1136/bmj.e3645
  39. Nissen, S. E.; Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Eng J Med 2007, 356 (24), 2457-2471.
  40. https://doi.org/10.1056/NEJMoa072761 DOI: https://doi.org/10.1056/NEJMoa072761
  42. Quianzon, C. C.; Cheikh, I. E., History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspec 2012, 2 (3).
  43. https://doi.org/10.3402/jchimp.v2i3.19081 DOI: https://doi.org/10.3402/jchimp.v2i3.19081
  45. Azoulay, L.; Yin, H.; Filion, K. B.; Assayag, J.; Majdan, A.; Pollak, M. N.; Suissa, S., The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012, 344.
  46. https://doi.org/10.1136/bmj.e3645 DOI: https://doi.org/10.1136/bmj.e3645
  48. Lincoff, A. M.; Wolski, K.; Nicholls, S. J.; Nissen, S. E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298 (10), 1180-1188.
  49. https://doi.org/10.1001/jama.298.10.1180 DOI: https://doi.org/10.1001/jama.298.10.1180
  51. Kim, J. W.; Kim, J.-R.; Yi, S.; Shin, K.-H.; Shin, H.-S.; Yoon, S. H.; Cho, J.-Y.; Kim, D.-H.; Shin, S.-G.; Jang, I.-J., Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-? agonist: a single-and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther 2011, 33 (11), 1819-1830.
  52. https://doi.org/10.1016/j.clinthera.2011.09.023 DOI: https://doi.org/10.1016/j.clinthera.2011.09.023
  54. Yasmin, S.; Jayaprakash, V., Design, In-Silico Docking And Predictive Adme Properties Of Some Thiazolidine-2, 4-Diones Derivatives As PPARG Modulators. Int J Pharm Pharm Sci 2016, 8 (5), 143-150.
  56. Guasch, L.; Sala, E.; Castell-Auví, A.; Cedó, L.; Liedl, K. R.; Wolber, G.; Muehlbacher, M.; Mulero, M.; Pinent, M.; Ardévol, A., Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation. PLoS One 2012, 7 (11), e50816.
  57. https://doi.org/10.1371/journal.pone.0050816 DOI: https://doi.org/10.1371/journal.pone.0050816
  59. Huang, N.; Shoichet, B. K.; Irwin, J. J., Benchmarking sets for molecular docking. J Med Chem 2006, 49 (23), 6789-6801.
  60. https://doi.org/10.1021/jm0608356 DOI: https://doi.org/10.1021/jm0608356
  62. Reddy, K. A.; Lohray, B.; Bhushan, V.; Bajji, A.; Reddy, K. V.; Reddy, P. R.; Krishna, T. H.; Rao, I. N.; Jajoo, H. K.; Rao, N. M., Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones. J Med Chem 1999, 42 (11), 1927-1940.
  63. https://doi.org/10.1021/jm980549x DOI: https://doi.org/10.1021/jm980549x
  65. Henke, B. R., Peroxisome proliferator-activated receptor a/? dual agonists for the treatment of type 2 diabetes. J Med Chem 2004, 47 (17), 4118-4127.
  66. https://doi.org/10.1021/jm030631e DOI: https://doi.org/10.1021/jm030631e
  68. Tomkinson, N. C.; Sefler, A. M.; Plunket, K. D.; Blanchard, S. G.; Parks, D. J.; Willson, T. M., Solid-phase synthesis of hybrid thiazolidinedione-fatty acid PPAR? ligands. Bioorg Med Chem Lett 1997, 7 (19), 2491-2496.
  69. https://doi.org/10.1016/S0960-894X(97)10017-8 DOI: https://doi.org/10.1016/S0960-894X(97)10017-8
  71. Pearlman, D. A.; Charifson, P. S., Improved scoring of ligand-protein interactions using OWFEG free energy grids. J Med Chem 2001, 44 (4), 502-511.
  72. https://doi.org/10.1021/jm000375v DOI: https://doi.org/10.1021/jm000375v
  74. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E., UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004, 25 (13), 1605-1612.
  75. https://doi.org/10.1002/jcc.20084 DOI: https://doi.org/10.1002/jcc.20084
  77. Schrödinger, L., Maestro 8.5 user manual. Schrödinger Press: 2008.
  79. Pires, D. E.; Blundell, T. L.; Ascher, D. B., pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem 2015, 58 (9), 4066-4072.
  80. https://doi.org/10.1021/acs.jmedchem.5b00104 DOI: https://doi.org/10.1021/acs.jmedchem.5b00104
  82. Laskowski, R. A.; Swindells, M. B., LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J Chem Inform Model 2011, 51 (10), 2778-2786.
  83. https://doi.org/10.1021/ci200227u DOI: https://doi.org/10.1021/ci200227u
  85. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V., Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-?. Nature 1998, 395 (6698), 137-143.
  86. https://doi.org/10.1038/25931 DOI: https://doi.org/10.1038/25931
  88. Lipinski, C. A., Lead-and drug-like compounds: the rule-of-five revolution. Drug Disc Today: Technologies 2004, 1 (4), 337-341.
  89. https://doi.org/10.1016/j.ddtec.2004.11.007 DOI: https://doi.org/10.1016/j.ddtec.2004.11.007
  91. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2012, 64, 4-17.
  92. https://doi.org/10.1016/j.addr.2012.09.019 DOI: https://doi.org/10.1016/j.addr.2012.09.019
  94. Zhang, M.-Q.; Wilkinson, B., Drug discovery beyond the 'rule-of-five'. Curr Opin Biotechnol 2007, 18 (6), 478-488.
  95. https://doi.org/10.1016/j.copbio.2007.10.005 DOI: https://doi.org/10.1016/j.copbio.2007.10.005
  97. Jorgensen, W. L.; Duffy, E. M., Prediction of drug solubility from structure. Adv Drug Deliv Rev 2002, 54 (3), 355-366.
  98. https://doi.org/10.1016/S0169-409X(02)00008-X DOI: https://doi.org/10.1016/S0169-409X(02)00008-X
  100. Egan, W. J.; Zlokarnik, G.; Grootenhuis, P. D., In silico prediction of drug safety: despite progress there is abundant room for improvement. Drug Disc Today: Technologies 2004, 1 (4), 381-387.
  101. https://doi.org/10.1016/j.ddtec.2004.11.002 DOI: https://doi.org/10.1016/j.ddtec.2004.11.002

Author information

Rights and permissions

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

About this article

Cite this article

(1)
Yasmin, S.; Mhlongo, N. N.; Soliman, M. E.; GR, S.; Jayaprakash, V. Comparative Design, In Silico Dockingand Predictive ADME TOX Properties of Some Novel 2, 4-Hydroxy Derivatives of Thiazolidine-2, 4-Diones As PPARγ Modulator. J Pharm Chem 2017, 4 (2), 11-19. https://doi.org/10.14805/jphchem.2017.art74.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX
Received
February 14, 2017
Published
May 25, 2017
Section
Research Articles
Pages
11-19

Keywords

  • PPARγ
  • virtual screening
  • enrichment study
  • molecular docking
  • predictive ADMET

Most read articles by the same author(s)

1 2 > >>